Keloids and hypertrophic scars: Pathophysiology, classification, and treatment

Dermatologic Surgery

Volumn 43, Issue , 2017, Pages S3-S18

  Berman, Brian ^a   Maderal, Andrea ^a   Raphael, Brian ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Micrographic Surgery and Dermatologic Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BOTULINUM TOXIN A; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; FLUOROURACIL; IMIQUIMOD; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; ONION EXTRACT; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; RETINOIC ACID; STEROID; TACROLIMUS; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; VERAPAMIL;

ALGORITHM; CLASSIFICATION; COMPRESSION THERAPY; CRYOSURGERY; DISEASE CLASSIFICATION; EXCISION; HUMAN; HYDROGEL; HYDROGEL SCAFFOLD; HYPERTROPHIC SCAR; KELOID; MEDICAL DEVICE; NONHUMAN; OCCLUSIVE DRESSING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SILICONE BASED CAMOUFLAGE; SKIN TENSION OFFLOADING DEVICE; TISSUE SCAFFOLD; WOUND HEALING; CICATRIX, HYPERTROPHIC; PHYSIOLOGY; SCAR;

ALGORITHMS; CICATRIX; CICATRIX, HYPERTROPHIC; HUMANS; KELOID; WOUND HEALING;

EID: 85010204545     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1097/DSS.0000000000000819     Document Type: Review

References (124)

1. Waehre T, Damas JK, Yndestad A, Pedersen TM, et al. Effect of activated platelets on expression of cytokines in peripheral blood mononuclear cells-potential role of prostaglandin E2. Thomb Haemost 2004;92:1358-67.
2. Lambert S, Frankart A, Poumay Y. p38 MAPK-regulated EGFR internalization takes place in keratinocyte monolayer during stress conditions. Arch Dermatol Res 2010;302:229-33.
3. Yates CC, Whaley D, Kulasekeran P, Hancock WW, et al. Delayed and deficient dermal maturation in mice lacking the CXCR3 ELRnegative CXC chemokine receptor. Am J Pathol 2007;171:484-95.
4. Michaels JV, Churgin SS, Blechman KM, Greives MR, et al. db/db mice exhibit severe wound-healing impairments compared with other murine diabetic strains in a silicone-splinted excisional wound model. Wound Repair Regen 2007;15:665-70.
5. Liechty KW, Adzick NS, Crombleholme TM. Diminished interleukin 6 (IL-6) production during scarless human fetal wound repair. Cytokine 2000;12:671-6.
6. van den Broek LJ, van der Veer WM, de Jong EH, Gibbs S, et al. Suppressed inflammatory gene expression during human hypertrophic scar compared to normotrophic scar formation. Exp Dermatol 2015; 24:623-9.
7. Liechty KW, Kim HB, Adzick NS, Crombleholme TM. Fetal wound repair results in scar formation in interleukin-10-deficient mice in a syngeneic murine model of scarless fetal wound repair. J Pediatr Surg 2000;35:866-72; discussion 872-3.
8. Namazi MR, Fallahzadeh MK, Schwartz RA. Strategies for prevention of scars: what can we learn from fetal skin? Int J Dermatol 2011;50: 85-93.
9. Martin P, D'Souza D, Martin J, Grose R, et al. Wound healing in the PU.1 null mouse-tissue repair is not dependent on inflammatory cells. Curr Biol 2003;13:1122-8.
10. Martin P, Dickson MC, Millan FA, Akhurst RJ. Rapid induction and clearance of TGF beta 1 is an early response to wounding in the mouse embryo. Dev Genet 1993;14:225-38.
11. Su CW, Alizadeh K, Boddie A, Lee RC. The problem scar. Clin Plast Surg 1998;25:451-65.
12. Shah M, Foreman DM, Ferguson MW. Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci 1994;107:1137-57.
13. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995;108:985-1002.
14. Shah M, Revis D, Herrick S, Baillie R, et al. Role of elevated plasma transforming growth factor-beta1 levels in wound healing. Am J Pathol 1999;154:1115-24.
15. Naitoh M, Hosokawa N, Kubota H, Tanaka T, et al. Upregulation of HSP47 and collagen type III in the dermal fibrotic disease, keloid. Biochem Biophys Res Commun 2001;280:1316-22.
16. Friedman DW, Boyd CD, Mackenzie JW, Norton P, et al. Regulation of collagen gene expression in keloids and hypertrophic scars. J Surg Res 1993;55:214-22.
17. Almine JF, Wise SG, Weiss AS. Elastin signaling in wound repair. Birth Defects Res C Embryo Today 2012;96:248-57.
18. Berman BA, Viera M. Keloid and hypertrophic scar. 2014 Mar. Available from: www.emedicine.medscape.com/article/1057599. Accessed November 13, 2015.
19. Berman B, Flores F. Comparison of a silicone gel-filled cushion and silicon gel sheeting for the treatment of hypertrophic or keloid scars. Dermatol Surg 1999;25:484-6.
20. O'Brien L, Jones DJ. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2013: CD003826.
21. Li Z, Dranoff JA, Chan EP, Uemura M, et al. Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 2007;46:1246-56.
22. Peyton SR, Putnam AJ. Extracellular matrix rigidity governs smooth muscle cell motility in a biphasic fashion. J Cell Physiol 2005;204:198-209.
23. Tanaydin V, Beugels J, Piatkowski A, Colla C, et al. Efficacy of custom-made pressure clips for ear keloid treatment after surgical excision. J Plast Reconstr Aesthet Surg 2016;69:115-21.
24. Hochman B, Locali RF, Matsuoka PK, Ferreira LM. Intralesional triamcinolone acetonide for keloid treatment: a systematic review. Aesthetic Plast Surg 2008;32:705-9.
25. Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids. Plast Reconstr Surg 2010;125:557-68.
26. Hayashi T, Furukawa H, Oyama A, Funayama E, et al. A new uniform protocol of combined corticosteroid injections and ointment application reduces recurrence rates after surgical keloid/hypertrophic scar excision. Dermatol Surg 2012;38:893-7.
27. Sadeghinia A, Sadeghinia S. Comparison of the efficacy of intralesional triamcinolone acetonide and 5-fluorouracil tattooing for the treatment of keloids. Dermatol Surg 2012;38:104-9.
28. Berman B, Flores F. Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections. J Am Acad Dermatol 1997;37:755-7.
29. Chaudhry MR, Akhtar S, Duvalsaint F, Garner L, et al. Ear lobe keloids, surgical excision followed by radiation therapy: a 10-year experience. Ear Nose Throat J 1994;73:779-81.
30. Sclafani AP, Gordon L, Chadha M, Romo T III. Prevention of earlobe keloid recurrence with postoperative corticosteroid injections versus radiation therapy: a randomized, prospective study and review of the literature. Dermatol Surg 1996;22:569-74.
31. Akita S, Akino K, Yakabe A, Imaizumi T, et al. Combined surgical excision and radiation therapy for keloid treatment. J Craniofac Surg 2007;18:1164-9.
32. Shepherd J, Dawber RP. The historical and scientific basis of cryosurgery. Clin Exp Dermatol 1982;7:321-8.
33. Har-Shai Y, Sabo E, Rohde E, Hyams M, et al. Intralesional cryosurgery enhances the involution of recalcitrant auricular keloids: a new clinical approach supported by experimental studies. Wound Repair Regen 2006;14:18-27.
34. Keeling BH, Whitsitt J, Liu A, Dunnick CA. Keloid removal by shave excision with adjuvant external beam radiation therapy. Dermatol Surg 2015;41:989-92.
35. van Leeuwen MC, Stokmans SC, Bulstra AE, Meijer OW, et al. Surgical excision with adjuvant irradiation for treatment of keloid scars: a systematic review. Plast Reconstr Surg Glob Open 2015;3: e440.
36. Ji J, Tian Y, Zhu YQ, Zhang LY, et al. Ionizing irradiation inhibits keloid fibroblast cell proliferation and induces premature cellular senescence. J Dermatol 2015;42:56-63.
37. Shen J, Lian X, Sun Y, Wang X, et al. Hypofractionated electron-beam radiation therapy for keloids: retrospective study of 568 cases with 834 lesions. J Radiat Res 2015;56:811-7.
38. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008;453:314-21.
39. McKeown SR, Hatfield P, Prestwich RJ, Shaffer RE, et al. Radiotherapy for benign disease; assessing the risk of radiationinduced cancer following exposure to intermediate dose radiation. Br J Radiol 2015;88:20150405.
40. Edwards L. The interferons. Dermatol Clin 2001;19:139-46.
41. Berman B, Duncan MR. Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J Am Acad Dermatol 1989;21: 694-702.
42. Tredget EE. The molecular biology of fibroproliferative disorders of the skin: potential cytokine therapeutics. Ann Plast Surg 1994;33: 152-4.
43. Harrop AR, Ghahary A, Scott PG, Forsyth N, et al. Regulation of collagen synthesis and mRNA expression in normal and hypertrophic scar fibroblasts in vitro by interferon-gamma. J Surg Res 1995;58: 471-7.
44. Tredget EE, Shankowsky HA, Pannu R, Nedelec B, et al. Transforming growth factor-beta in thermally injured patients with hypertrophic scars: effects of interferon alpha-2b. Plast Reconstr Surg 1998;102:1317-28; discussion 1329-30.
45. al-Khawajah MM. Failure of interferon-alpha 2b in the treatment of mature keloids. Int J Dermatol 1996;35:515-7.
46. Lee JH, Kim SE, Lee AY. Effects of interferon-alpha2b on keloid treatment with triamcinolone acetonide intralesional injection. Int J Dermatol 2008;47:183-6.
47. Darougheh A, Asilian A, Shariati F. Intralesional triamcinolone alone or in combination with 5-fluorouracil for the treatment of keloid and hypertrophic scars. Clin Exp Dermatol 2009;34:219-23.
48. Nanda S, Reddy BS. Intralesional 5-fluorouracil as a treatment modality of keloids. Dermatol Surg 2004;30:54-6; discussion 56-7.
49. Kontochristopoulos G, Stefanaki C, Panagiotopoulos A, Stefanaki K, et al. Intralesional 5-fluorouracil in the treatment of keloids: an open clinical and histopathologic study. J Am Acad Dermatol 2005; 52:474-9.
50. Bijlard E, Steltenpool S, Niessen FB. Intralesional 5-fluorouracil in keloid treatment: a systematic review. Acta Derm Venereol 2015;95: 778-82.
51. Haurani MJ, Foreman K, Yang JJ, Siddiqui A. 5-Fluorouracil treatment of problematic scars. Plast Reconstr Surg 2009;123:139-48; discussion 149-51.
52. Shin JY, Kim JS. Could 5-fluorouracil or triamcinolone be an effective treatment option for keloid after surgical excision? A meta-analysis. J Oral Maxillofac Surg 2015;74:1055-60.
53. Jones CD, Guiot L, Samy M, Gorman M, et al. The Use of Chemotherapeutics for the treatment of keloid scars. Dermatol Rep 2015;7:5880.
54. Martin-Garcia RF, Busquets AC. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Dermatol Surg 2005;31:1394-8.
55. Jacob SE, Berman B, Nassiri M, Vincek V. Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis. Br J Dermatol 2003;149(Suppl 66):62-5.
56. Berman B, Kaufman J. Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002;47:S209-11.
57. Chuangsuwanich A, Gunjittisomram S. The efficacy of 5% imiquimod cream in the prevention of recurrence of excised keloids. J Med Assoc Thai 2007;90:1363-7.
58. Cacao FM, Tanaka V, Messina MC. Failure of imiquimod 5% cream to prevent recurrence of surgically excised trunk keloids. Dermatol Surg 2009;35:629-33.
59. Berman B, Harrison-Balestra C, Perez OA, Viera M, et al. Treatment of keloid scars post-shave excision with imiquimod 5% cream: a prospective, double-blind, placebo-controlled pilot study. J Drugs Dermatol 2009;8:455-8.
60. Wu CS, Wu PH, Fang AH, Lan CC. FK506 inhibits the enhancing effects of transforming growth factor (TGF)-beta1 on collagen expression and TGF-beta/Smad signalling in keloid fibroblasts: implication for new therapeutic approach. Br J Dermatol 2012;167: 532-41.
61. Kim A, Di Carlo J, Cohen C, McCall C, et al. Are keloids really "gli-loids"?: high-level expression of gli-1 oncogene in keloids. J Am Acad Dermatol 2001;45:707-11.
62. Gisquet H, Liu H, Blondel WC, Leroux A, et al. Intradermal tacrolimus prevent scar hypertrophy in a rabbit ear model: a clinical, histological and spectroscopical analysis. Skin Res Technol 2011;17: 160-6.
63. Berman B, Villa AM. An open-label pilot study to evaluate the safety and tolerability of tacrolimus ointment 0.1% for the treatment of keloids. Cosmet Dermatol 2007;18:399-404.
64. Ong CT, Khoo YT, Mukhopadhyay A, Do DV, et al. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol 2007;16:394-404.
65. Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004;279:23166-75.
66. Zhu J, Wu J, Frizell E, Liu SL, et al. Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999;117:1198-204.
67. Park J, Ha H, Ahn HJ, Kang SW, et al. Sirolimus inhibits plateletderived growth factor-induced collagen synthesis in rat vascular smooth muscle cells. Transplant Proc 2005;37:3459-62.
68. Wong VW, You F, Januszyk M, Gurtner GC, et al. Transcriptional profiling of rapamycin-treated fibroblasts from hypertrophic and keloid scars. Ann Plast Surg 2014;72:711-9.
69. Syed F, Sanganee HJ, Singh S, Bahl A, et al. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity. J Invest Dermatol 2013;133:1340-50.
70. Saray Y, Gulec AT. Treatment of keloids and hypertrophic scars with dermojet injections of bleomycin: a preliminary study. Int J Dermatol 2005;44:777-84.
71. Yeowell HN, Marshall MK, Walker LC, Ha V, et al. Regulation of lysyl oxidase mRNA in dermal fibroblasts from normal donors and patients with inherited connective tissue disorders. Arch Biochem Biophys 1994;308:299-305.
72. Espana A, Solano T, Quintanilla E. Bleomycin in the treatment of keloids and hypertrophic scars by multiple needle punctures. Dermatol Surg 2001;27:23-7.
73. Muszynska A, Palka J, Wolczynski S. Doxorubicin-induced inhibition of prolidase activity in human skin fibroblasts and its implication to impaired collagen biosynthesis. Pol J Pharmacol 1998; 50:151-7.
74. Sasaki T, Holeyfield KC, Uitto J. Doxorubicin-induced inhibition of prolyl hydroxylation during collagen biosynthesis in human skin fibroblast cultures. Relevance to imparied wound healing. J Clin Invest 1987;80:1735-41.
75. Muszynska A, Wolczynski S, Palka J. The mechanism for anthracycline-induced inhibition of collagen biosynthesis. Eur J Pharmacol 2001;411:17-25.
76. O'Kane S, Ferguson MW. Transforming growth factor beta s and wound healing. Int J Biochem Cell Biol 1997;29:63-78.
77. Schrementi ME, Ferreira AM, Zender C, Di Pietro LA. Site-specific production of TGF-beta in oral mucosal and cutaneous wounds. Wound Repair Regen 2008;16:80-6.
78. Smith P, Mosiello G, Deluca L, Ko F, et al. TGF-beta2 activates proliferative scar fibroblasts. J Surg Res 1999;82:319-23.
79. Occleston NL, O'Kane S, Laverty HG, Cooper M, et al. Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen 2011;19(Suppl 1): s38-48.
80. Ferguson MW, Duncan J, Bond J, Bush J, et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 2009;373: 1264-74.
81. So K, McGrouther DA, Bush JA, Durani P, et al. Avotermin for scar improvement following scar revision surgery: a randomized, doubleblind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg 2011;128:163-72.
82. Young L. Trial of Juvista (Avotermin) following removal of ear lobe keloid scars. Available from: https://clinicaltrials.gov/ct2/show/NCT00469235. Accessed November 15, 2015.
83. Young V. Exploratory study of the efficacy and safety of Juvista 250 ng when administered following excision of ear lobe keloids. Available from: https://clinicaltrials.gov/ct2/show/NCT00836147. Accessed November 15, 2015.
84. Young V. Safety of Juvista when administered following excision of ear lobe keloids (RN1001-0093). Available from: https://clinicaltrials.gov/ct2/show/NCT00710333. Accessed November 15, 2015.
85. Nanney LB. Epidermal and dermal effects of epidermal growth factor during wound repair. J Invest Dermatol 1990;94:624-9.
86. Peled ZM, Rhee SJ, Hsu M, Chang J, et al. The ontogeny of scarless healing II: EGF and PDGF-B gene expression in fetal rat skin and fibroblasts as a function of gestational age. Ann Plast Surg 2001;47: 417-24.
87. Brown GL, Curtsinger L III, Brightwell JR, Ackerman DM, et al. Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J Exp Med 1986;163:1319-24.
88. Epstein JB, Gorsky M, Guglietta A, Le N, et al. The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 2000; 89:2258-65.
89. Kim YS, Lew DH, Tark KC, Rah DK, et al. Effect of recombinant human epidermal growth factor against cutaneous scar formation in murine full-thickness wound healing. J Korean Med Sci 2010;25: 589-96.
90. Shin JU, Kang SW, Jeong JJ, Nam KH, et al. Effect of recombinant human epidermal growth factor on cutaneous scar quality in thyroidectomy patients. J Dermatolog Treat 2015;26: 159-64.
91. Seidel R, Moy RL. Improvement in atrophic acne scars using topical synthetic epidermal growth factor (EGF) serum: a pilot study. J Drugs Dermatol 2015;14:1005-10.
92. Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004;47:34-57.
93. Margaret Shanthi FX, Ernest K, Dhanraj P. Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 2008;74:343-8.
94. Doong H, Dissanayake S, Gowrishankar TR, La Barbera MC, et al. The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. J Burn Care Rehabil 1996;17:497-514.
95. D'Andrea F, Brongo S, Ferraro G, Baroni A. Prevention and treatment of keloids with intralesional verapamil. Dermatology 2003; 204:60-2.
96. Lawrence WT. Treatment of earlobe keloids with surgery plus adjuvant intralesional verapamil and pressure earrings. Ann Plast Surg 1996;37:167-9.
97. Uchida G, Yoshimura K, Kitano Y, Okazaki M, et al. Tretinoin reverses upregulation of matrix metalloproteinase-13 in human keloid-derived fibroblasts. Exp Dermatol 2003;12(Suppl 2):35-42.
98. Daly TJ, Weston WL. Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic disease in vivo. J Am Acad Dermatol 1986;15:900-2.
99. Abergel RP, Meeker CA, Oikarinen H, Oikarinen AI, et al. Retinoid modulation of connective tissue metabolism in keloid fibroblast cultures. Arch Dermatol 1985;121:632-5.
100. Janssen de Limpens AM. The local treatment of hypertrophic scars and keloids with topical retinoic acid. Br J Dermatol 1980;103: 319-23.
101. Panabiere-Castaings MH. Retinoic acid in the treatment of keloids. J Dermatol Surg Oncol 1988;14:1275-6.
102. Kwon SY, Park SD, Park K. Comparative effect of topical silicone gel and topical tretinoin cream for the prevention of hypertrophic scar and keloid formation and the improvement of scars. J Eur Acad Dermatol Venereol 2014;28:1025-33.
103. Blackwell KL, Haroon ZA, Shan S, Saito W, et al. Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res 2000;6:4359-64.
104. Kinzbrunner B, Ritter S, Domingo J, Rosenthal CJ. Remission of rapidly growing desmoid tumors after tamoxifen therapy. Cancer 1983;52:2201-4.
105. Clark CP, Vanderpool D, Preskitt JT. The response of retroperitoneal fibrosis to tamoxifen. Surgery 1991;109:502-6.
106. Mancoll JS, Zhao J, McCauley RL, Phillips LG. The inhibitory effect of tamoxifen on keloid fibroblasts. Surg Forum 1996;47:718-20.
107. Hu D, Hughes MA, Cherry GW. Topical tamoxifen-a potential therapeutic regime in treating excessive dermal scarring? Br J Plast Surg 1998;51:462-9.
108. Mikulec AA, Hanasono MM, Lum J, Kadleck JM, et al. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg 2001;3:111-4.
109. Pasquetti AF, Mota WN, Dos Santos MR, Farias Brito HL. Uso do tamoxifeno no tratamento de queloides e cicatrizes hipertroficas. Rev Bras Cir Plast 2010;25:372-8.
110. Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg 2009;33:409-12.
111. Zhibo X, Miaobo Z. Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. J Plast Reconstr Aesthet Surg 2008;61:1128-9.
112. Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg 2009;124: 275e-7e.
113. Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, et al. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol 2012;25: 313-8.
114. Robinson AJ, Khadim MF, Khan K. Keloid scars and treatment with botulinum toxin type A: the Belfast experience. J Plast Reconstr Aesthet Surg 2013;66:439-40.
115. Saulis AS, Mogford JH, Mustoe TA. Effect of Mederma on hypertrophic scarring in the rabbit ear model. Plast Reconstr Surg 2003;110:177-83; discussion 184-6.
116. Kikuchi K, Kadono T, Takehara K. Effects of various growth factors and histamine on cultured keloid fibroblasts. Dermatology 1995;190:4-8.
117. Kupietzky A, Levi-Schaffer F. The role of mast cell-derived histamine in the closure of an in vitro wound. Inflamm Res 1996;45:176-80.
118. Koc E, Arca E, Surucu B, Kurumlu Z. An open, randomized, controlled, comparative study of the combined effect of intralesional triamcinolone acetonide and onion extract gel and intralesional triamcinolone acetonide alone in the treatment of hypertrophic scars and keloids. Dermatol Surg 2008;34:1507-14.
119. Hosnuter M, Payasli C, Isikdemir A, Tekerekoglu B. The effects of onion extract on hypertrophic and keloid scars. J Wound Care 2007; 16:251-4.
120. Viera MH, Caperton CV, Berman B. Advances in the treatment of keloids. J Drugs Dermatol 2011;10:468-80.
121. Berman B, Garikaparthi S, Smith E, Newburger J. A novel hydrogel scaffold for the prevention or reduction of the recurrence of keloid scars postsurgical excision. J Am Acad Dermatol 2013;69:828-30.
122. Wong VW, Rustad KC, Akaishi S, Sorkin M, et al. Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling. Nat Med 2012;18:148-52.
123. Longaker MT, Rohrich RJ, Greenberg L, Furnas H, et al. A randomized controlled trial of the embrace advanced scar therapy device to reduce incisional scar formation. Plast Reconstr Surg 2014; 134:536-46.
124. Gold MH, McGuire M, Mustoe TA, Pusic A, et al. Updated international clinical recommendations on scar management: part 2-algorithms for scar prevention and treatment. Dermatol Surg 2014;40:825-31.